Female gene expression in the seminal vesicle of mice after prenatal exposure to diethylstilbestrol. 1989

R R Newbold, and B T Pentecost, and S Yamashita, and K Lum, and J V Miller, and P Nelson, and J Blair, and H Kong, and C Teng, and J A McLachlan
Developmental Endocrinology and Pharmacology Section, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709.

Previous studies from our laboratory on the feminization of the male mouse reproductive tract after prenatal exposure to diethylstilbestrol (DES) showed that the mRNA for the major estrogen-inducible uterine secretory protein, lactoferrin (LF), was constitutively expressed in the seminal vesicle of male mice exposed prenatally to DES, but not in the seminal vesicle of control mice. After castration, treatment with 17 beta-estradiol (20 micrograms/kg.day) for 3 days induced the LF mRNA in the seminal vesicle of both control and prenatally DES-exposed mice; however, the levels in DES-treated tissues were approximately 6-fold higher than those in control tissue. This report describes the presence of LF in seminal vesicle tissues and secretions of prenatally DES-exposed mice, as determined by immunohistochemistry and Western blot analysis. Further, these data are correlated with immunolocalization of the estrogen receptor in the seminal vesicle tissue. We conclude that the seminal vesicle of prenatally DES-exposed male mice has acquired two key characteristics of female tissues, namely LF production/regulation and estrogen receptor localization/distribution similar to that in uterine tissues.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007781 Lactoferrin An iron-binding protein that was originally characterized as a milk protein. It is widely distributed in secretory fluids and is found in the neutrophilic granules of LEUKOCYTES. The N-terminal part of lactoferrin possesses a serine protease which functions to inactivate the TYPE III SECRETION SYSTEM used by bacteria to export virulence proteins for host cell invasion. Lactotransferrin
D008297 Male Males
D009919 Orchiectomy The surgical removal of one or both testicles. Castration, Male,Orchidectomy,Castrations, Male,Male Castration,Male Castrations,Orchidectomies,Orchiectomies
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011297 Prenatal Exposure Delayed Effects The consequences of exposing the FETUS in utero to certain factors, such as NUTRITION PHYSIOLOGICAL PHENOMENA; PHYSIOLOGICAL STRESS; DRUGS; RADIATION; and other physical or chemical factors. These consequences are observed later in the offspring after BIRTH. Delayed Effects, Prenatal Exposure,Late Effects, Prenatal Exposure
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D001826 Body Fluids Liquid components of living organisms. Body Fluid,Fluid, Body,Fluids, Body
D004054 Diethylstilbestrol A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) Stilbestrol,Agostilben,Apstil,Diethylstilbestrol, (Z)-Isomer,Diethylstilbestrol, Disodium Salt,Distilbène,Stilbene Estrogen,Tampovagan,Estrogen, Stilbene
D005260 Female Females

Related Publications

R R Newbold, and B T Pentecost, and S Yamashita, and K Lum, and J V Miller, and P Nelson, and J Blair, and H Kong, and C Teng, and J A McLachlan
May 1994, The Journal of urology,
R R Newbold, and B T Pentecost, and S Yamashita, and K Lum, and J V Miller, and P Nelson, and J Blair, and H Kong, and C Teng, and J A McLachlan
January 1977, Journal of toxicology and environmental health,
R R Newbold, and B T Pentecost, and S Yamashita, and K Lum, and J V Miller, and P Nelson, and J Blair, and H Kong, and C Teng, and J A McLachlan
January 1980, Journal of immunology (Baltimore, Md. : 1950),
R R Newbold, and B T Pentecost, and S Yamashita, and K Lum, and J V Miller, and P Nelson, and J Blair, and H Kong, and C Teng, and J A McLachlan
January 2024, Journal of xenobiotics,
R R Newbold, and B T Pentecost, and S Yamashita, and K Lum, and J V Miller, and P Nelson, and J Blair, and H Kong, and C Teng, and J A McLachlan
March 1980, Journal of immunology (Baltimore, Md. : 1950),
R R Newbold, and B T Pentecost, and S Yamashita, and K Lum, and J V Miller, and P Nelson, and J Blair, and H Kong, and C Teng, and J A McLachlan
April 2020, Molecular biology and evolution,
R R Newbold, and B T Pentecost, and S Yamashita, and K Lum, and J V Miller, and P Nelson, and J Blair, and H Kong, and C Teng, and J A McLachlan
April 2012, Environmental health perspectives,
R R Newbold, and B T Pentecost, and S Yamashita, and K Lum, and J V Miller, and P Nelson, and J Blair, and H Kong, and C Teng, and J A McLachlan
February 2008, Fertility and sterility,
R R Newbold, and B T Pentecost, and S Yamashita, and K Lum, and J V Miller, and P Nelson, and J Blair, and H Kong, and C Teng, and J A McLachlan
October 1983, The Journal of pharmacology and experimental therapeutics,
R R Newbold, and B T Pentecost, and S Yamashita, and K Lum, and J V Miller, and P Nelson, and J Blair, and H Kong, and C Teng, and J A McLachlan
April 1988, Cancer letters,
Copied contents to your clipboard!